In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness

  title={In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness},
  author={Tanja Wenzler and Sihyung Yang and Donald A Patrick and Olivier Braissant and Mohamed A. Ismail and Richard R. Tidwell and David W Boykin and Michael Zhuo Wang and Reto Brun},
  journal={Antimicrobial Agents and Chemotherapy},
  pages={4452 - 4463}
ABSTRACT African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple diamidine found to cure mice with central nervous system infections by a parenteral route of administration. 28DAP010 showed efficacy similar to that of DB829 in dose-response studies in mouse models of first- and second-stage African… 

In Vitro and In Vivo Studies of the Trypanocidal Effect of Novel Quinolines

These quinolines showed high probabilities of Caco2 permeability and human intestinal absorption and low probabilities of mutagenicity and of hERG1 inhibition, and revealed that most molecules did not infringe on Lipinski's rules, which is a prediction of good oral absorption.

Novel lead compounds in pre-clinical development against African sleeping sickness.

In this review, the different strategies of drug development against HAT are considered, namely the target-based approach, the phenotypic high throughput screening and the drug repurposing strategy.

Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies

Pafuramidine for the treatment of first stage HAT was comparable in efficacy to pentamidine after 10 days of dosing, and results support continuation of the development program for pafur amidine into Phase 3.

Antileishmanial Mechanism of Diamidines Involves Targeting Kinetoplasts

Results suggest that diamidine antileishmanial compounds exert activity by accumulating toward and blocking replication of parasite kDNA, but not nDNA, replication.

Characterization of recombinant Trypanosoma brucei gambiense Translationally Controlled Tumor Protein (rTbgTCTP) and its interaction with Glossina midgut bacteria

The potential for TCTP to modulate the fly microbiome composition toward favoring trypanosome survival is discussed, and it was shown to affect the growth of the majority of these bacteria, especially when cultivated under microaerobiosis and anaerobiotics.

Murine Models for Development of Anti-Infective Therapeutics

Specific bacterial, fungal, viral, protozoal, and helminth diseases modeled in mouse and rat models for testing the efficacy of a particular drug molecule under study are elaborates on.

Treatment options for second-stage gambiense human African trypanosomiasis

The main scope of this article is to discuss the potential impact of new oral therapies to improve diagnosis-treatment algorithms and patients’ access to treatment, and to contribute to reach the objectives of the recently launched gambiense human African trypanosomiasis elimination program.

From Molecule to Drug

An overview on antiparasitic drug targets is given and the research and development pipeline with recent success stories for malaria and human African trypanosomiasis is illustrated.



Biological and pharmacological investigations of novel diamidines in animal models of human African trypanosomiasis

Biological and pharmacological investigations of potential new drug candidates in animal models of HAT with the objective of contributing to the development of safe, efficacious and easy to use treatments for HAT are carried out.

Pharmacokinetics, Trypanosoma brucei gambiense Efficacy, and Time of Drug Action of DB829, a Preclinical Candidate for Treatment of Second-Stage Human African Trypanosomiasis

Isothermal microcalorimetry and in vivo time-to-kill studies revealed that DB829 is a slower-acting trypanocidal compound than pentamidine, which is a promising preclinical candidate for the treatment of first- and second-stage HAT caused by both Trypanosoma brucei subspecies.

Pharmacokinetic Comparison To Determine the Mechanisms Underlying the Differential Efficacies of Cationic Diamidines against First- and Second-Stage Human African Trypanosomiasis

The results showed that DB829, an azadiamidine, had the highest systemic exposure and brain-to-plasma ratio, whereas pentamidine and DB75 had the lowest, and none of these diamidines was a P-gp substrate, and the binding of each to plasma proteins and brain differed greatly.

The phenomenon of treatment failures in Human African Trypanosomiasis

A combination of factors rather than a single one may be responsible for the phenomenon of melarsoprol treatment failures in T. b.

Isolation of Trypanosoma brucei gambiense from Cured and Relapsed Sleeping Sickness Patients and Adaptation to Laboratory Mice

A unique collection of T.b. gambiense from cured and relapsed patients, isolated in the same disease focus and within a limited period is established to investigate the mechanism behind abnormally high treatment failure rates in Mbuji-Mayi, D.R. Congo.

Development of novel drugs for human African trypanosomiasis.

Novel benzoxaboroles, discovered by Anacor, Scynexis and DNDi, have good pharmacokinetic properties in plasma and in the brain and are curative in a murine model of stage two HAT with brain infection.

Mechanisms of Arsenical and Diamidine Uptake and Resistance in Trypanosoma brucei

The role of TbAT1 in drug uptake and drug resistance in T. brucei is investigated and a reduction in drug sensitivity is presented, since mice infected with tbat1-null trypanosomes could not be cured with 2 mg of melarsoprol/kg of body weight for four consecutive days, whereas mice infectedwith the parental line were all cured by using this protocol.

Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story.

Antiparasitic agents: new drugs on the horizon.